Botulinum toxin type A for the treatment of migraine

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 8, 2006, Pages 1085-1095

  Aurora, Sheena ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Botulinum toxin; Chronic daily headache; Chronic migraine; Transformed migraine

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIPLOPIA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FREQUENCY ANALYSIS; HEADACHE; HUMAN; INJECTION SITE PAIN; MUSCLE WEAKNESS; NAUSEA; NECK PAIN; PHOTOPHOBIA; PROPHYLAXIS; PTOSIS; SKIN TIGHTNESS; STATISTICAL SIGNIFICANCE; TRANSFORMED MIGRAINE;

BOTULINUM TOXIN TYPE A; DRUGS, INVESTIGATIONAL; HUMANS; INJECTIONS, INTRAMUSCULAR; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 33745459807     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.8.1085     Document Type: Article

References (58)

1. SILBERSTEIN SD, LIPTON RB: Chronic daily headache. Curr. Opin. Neurol. (2000) 13(3):277-283.
2. BIGAL ME, TEPPER SJ, SHEFTELL FD, RAPOPORT AM, LIPTON RB: Field testing alternative criteria for chronic migraine. Cephalalgia (2006) 26:477-482.
3. LIPTON RB, STEWART WF, DIAMOND S, DIAMOND ML, REED M: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache (2001) 41(7):646-657.
4. SCHER AI, STEWART WF, LIBERMAN J, LIPTON RB: Prevalence of frequent headache in a population sample. Headache (1998) 38:497-506.
5. CASTILLO J, MUNOZ P, GUITERA V, PASCUAL J: Epidemiology of chronic daily headache in the general population. Headache (1999) 39:190-196.
6. BIGAL ME, LIPTON RB, TEPPER SJ, RAPOPORT AM, SHEFTELL FD: Primary chronic daily headache and its subtypes in adolescents and adults. Neurology (2004) 63(5):843-847.
7. BIGAL ME, RAPOPORT AM, LIPTON RB, TEPPER SJ, SHEFTELL FD: Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache (2003) 43(4):336-342.
8. DURU G, AURAY JP, GAUDIN AF, DARTIGUES JF et al.: Impact of headache on quality of life in a general population survey in France (GRIM2000 Study). Headache (2004) 44(6):571-580.
9. GUITERA V, MUNOZ P CASTILLO J, PASCUAL J: Quality of life in chronic daily headache: a study in a general population. Neurology (2002) 58(7):1062-1065.
10. SILBERSTEIN SD: Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2000) 55(6):754-762.
11. MATHEW NT: Antiepileptic drugs in migraine prevention. Headache (2001) 41(Suppl. 1):S18-S24.
12. SILBERSTEIN SD, NETO W. SCHMITT J, JACOBS D, MIGR-001 STUDY GROUP: Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol (2004) 61:490-495.
13. LINDE K, ROSSNAGEL K: Propranolol for migraine prophylaxis. Cochrane Database Syst. Rev. (2004) 2:CD003225.
14. GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine - current understanding and treatment. N. Engl. J. Med (2002) 346:257-270.
15. ASHKENAZI A, SILBERSTEIN SD: Hormone-related headache: pathophysiology and treatment. CNS Drugs (2006) 20:125-141.
16. SILVESTRINI M, BARTOLINI M, COCCIA M, BARUFFALDI R, TAFFI R, PROVINCIALI L: Topiramate in the treatment of chronic migraine. Cephalalgia (2003) 23(8):820-824.
17. SAPER JR, LAKE AE III, CANTRELL DT, WINNER PK, WHITE JR: Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache (2002) 42(6):470-482.
18. SPIRA PJ, BERAN RG; AUSTRALIAN GABAPENTIN CHRONIC DAILY HEADACHE GROUP: Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology (2003) 61(12):1753-1759.
19. SAPER JR, SILBERSTEIN SD, LAKE AE III, WINTERS ME: Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache (1994) 34(9):497-502.
20. GAWEL MJ, KREEFT J, NELSON RF, SIMARD D, ARNOTT WS: Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can. J. Neurol. Sci (1992) 19(3):340-345.
21. SILBERSTEIN S, MATHEW N, SAPER J, JENKINS S: Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group, Headache (2000) 40(6):445-450.
22. MATHEW NT, FRISHBERG BM, GAWEL M, DIMITROVA R, GIBSON J, TURKEL C; BOTOX CDH STUDY GROUP: Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache (2005) 45(4):293-307.
23. DODICK DW, MAUSKOP A, ELKIND AH, DEGRYSE R, BRIN MF, SILBERSTEIN SD; BOTOX CDH STUDY GROUP: Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache (2005) 45(4):315-324.
24. SCOTT AB, KENNEDY RA, STUBBS HA: Botulinum A toxin injection as a treatment for blepharospasm. Arch. Ophthalmol. (1985) 103(3):347-350.
25. SCOTT AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology (1980) 87(10):1044-1049.
26. TSUI JK, EISEN A, STOESSL AJ, CAINE S, CALNE DB: Double-blind study of botulinum toxin in spasmodic torticollis. Lancet (1986) 2(8501):245-247.
27. BORODIC GE, ACQUADRO M, JOHNSON EA: Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin. Investig. Drugs (2001) 10(8):1531-1544.
28. SAKAGUCHI G, KOZAKI S, OHISHI I: Structure and function of botulinum toxins. In: Bacterial Protein Toxins. Alouf JE (ed), Academic Press, London (1984):435-443.
29. ZHANG L, LIN WJ, LI S, AOKI KR: Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain. Gene (2003) 315:21-32.
30. CHEN F, KUZIEMKO GM, STEVENS RC: Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect. Immun. (1998) 6(6):2420-2425.
31. SHARMA SK, SINGH BR: Hemagglutinin binding mediated protection of botulinum neurotoxin from proteolysis. J. Nat. Toxins (1998) 7(3):239-253.
32. SCHANTZ EJ, JOHNSON EA: Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. (1992) 56(1):80-99.
33. BRIN MF, AOKI KR, DRESSLER D: Pharmacology of botulinum toxin therapy In: Dystonia: Etiology, Clinical Features, and Treatment. Brin MF, Comella C, Jankovic J (Eds.), Lippincott, Williams & Wilkins, Philadelphia (2004):93-112.
34. SCHUITE-MATTLER WJ, KRACK P: Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain (2004) 109:110-114.
35. ROLLNIK JD, DENGLER R: Botulinum toxin (DYSPORT) in tension-type headaches. Acta Neurochir. Suppl. (2002) 79:123-126.
36. SAMPAIO C, COSTA J, FERREIRA JJ: Clinical comparability of marketed formulations of botulinum toxin. Mov. Disord. (2004) 19(Suppl. 8):S129-Sl36.
37. BLACK JD, DOLLY JO: Interaction of 1251-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves.J. Cell Biol. (1986) 103(2):521-534.
38. BLACK JD, DOLLY JO: Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J. Cell Biol. (1986) 103(2):535-544.
39. DOLLY O: Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache (2003) 43(Suppl. 1):S16-S24.
40. SMUTS JA, SCHULTZ D, BARNARD A: Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache (2004) 44(8):801-805.
41. WELCH MJ, PURKISS JR, FOSTER KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. (2000) 38(2):245-258.
42. CHUANG YC, YOSHIMURA N, HUANG CC, CHIANG PH, CHANCELLOR MB: Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J. Urol. (2004) 172(4 Pt 1):1529-1532.
43. DURHAM PL, CADY R, CADY R: Regulation of calcitonin gene-related peptide secretion from trigerninal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache (2004) 44(1):35-42.
44. CUI M, KHANIJOU S, RUBINO J, AOKI KR: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain (2004) 107(1-2):125-133.
45. AOKI KR: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxilogy (2005) 26(5):785-793.
46. BENDTSEN L, MATTSSON P, ZWART JA, LIPTON RB: Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia (2003) 23(7):487-490.
47. BARRIENTOS N, CHANA P: Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J. Headache Pain (2003) 4(3):146-151.
48. EVERS S, VOLLMER-HAASE J, SCHWAAG S, RAHMANN A, HUSSTEDT IW, FRESE A: Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia (2004) 24(10):838-843.
49. SAPER JR, MATHEW NT, LODER EW, DEGRYSE R, VANDENBURGH AM FOR THE BONTA-009 STUDY GROUP: A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med (in press).
50. ELKIND AH, O'CARROLL P, BLUMENFELD A, DEGRYSE R, DIMITROVA R, FOR THE BONTA-024-026-036 STUDY GROUP: A series of 3 sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J. Pain (in press).
51. AURORA SK, GAWEL M, BRANDES JL, POKTA S, VANDENBURGH AM: Botulinum toxin type A prophylactic treatment for episodic migraine using a modified follow-the-pain treatment paradigm: a randomized, double-blind, placebo controlled, phase II study. Presented at the 47th Annual Scientific Meeting of the American Headache Society. Philadelphia, PA, USA (2005).
52. RELJA M, POOLE AC, SCHOENEN J, PASCUAL J, SAULAY M, KUMAR C: A multicenter, double-blind, randomized, placebo-controlled, parallel group study of multiple treatment of botulinum toxin type A (BoNTA) for the prophylaxis of migraine headaches. Presented at the 15th Meeting of the European Neurological Society. Vienna, Austria (2005).
53. ONDO WG, VUONG KD, DERMAN HS: Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia (2004) 24(1):60-65.
54. SILBERSTEIN SD, LIPTION RB, SOLOMON S MATHEW NT: Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache (1994) 34:1-7.
55. HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: The international classification of headache disorders: 2nd edition. Cephalalgia (2004) 24(Suppl 1):9-160.
56. SAPER JR, BRANDES JL, WRUBEL B, DODICK DW: Botulinum toxin type A treatment of chronic daily headache in migraineurs overusing analgesics and not taking concomitant prophylactics. Presented at the 47th Annual Scientific Meeting of the American Headache Society. Philadelphia, PA, USA (2005).
57. AURORA SK, VANDENBURGH AM: Botulinum toxin type A for the prophylaxis of chronic daily headache in migraineurs: effect on the frequency of headaches of ≥ 4 hours duration (a randomized, double-blind, placebo-controlled study). Presented at the 12th Congress of the International Headache Society. Kyoto, Japan (2005).
58. SILBERSTEIN SD, STARK SR, LUCAS SM, CHRISTIE SN, DEGRYSE RE, TURKEL CC; BONTA-039 STUDY GROUP: Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. (2005) 80(9):1126-1137.